Pyridinyl Morpholine Compounds for D2/D3 and 5-HT2A Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antipsychotic drugs for schizophrenia primarily target the D2 receptor, offering limited efficacy for negative symptoms and cognitive impairment, and are associated with significant side effects such as EPS, hyperprolactinemia, obesity, sedation, and anxiety due to non-selective receptor binding, particularly with the H1 receptor.
Innovation Solution
Development of a pyridinyl morpholine compound with strong affinity for D2, D3, and 5-HT2A receptors, and selective antagonism for D3/D2 receptors, while minimizing H1 receptor affinity to reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical antipsychotic drugs act on D2 receptor, then positive symptoms are treated, but extrapyramidal effects and hyperprolactinemia occur due to excessive antagonism
Solution Approach 1:
The patent modifies the chemical structure parameters of antipsychotic drugs by introducing specific substituents at defined positions in the molecular structure, which alters the receptor binding characteristics to reduce excessive D2 antagonism while maintaining therapeutic efficacy
Solution Approach 2:
The patent applies local quality modification by placing specific functional groups at particular positions (R1 at position 1, R2 at position 2, R3 at position 3) of the core molecular structure, creating localized interactions that modulate receptor selectivity and reduce side effects
2Reliability
If classical antipsychotic drugs act solely on DA-ergic system, then positive symptoms are treated, but negative symptom and cognitive impairment remain ineffective
Solution Approach 1:
The patent designs compounds with multi-functional capability by incorporating structural features that enable simultaneous interaction with multiple neurotransmitter systems (dopamine, serotonin, norepinephrine), allowing a single drug to address positive symptoms, negative symptoms, and cognitive impairment
Solution Approach 2:
The patent merges multiple pharmacological actions into a single molecular structure by combining D2 antagonism, 5-HT2A antagonism, and norepinephrine reuptake inhibition properties in one compound, expanding the therapeutic spectrum
3Adaptability or versatility
If non-classical antipsychotic drugs act on D2 and 5-HT2A receptors, then both positive and negative symptoms are treated, but cognitive function shows no significant improvement and side effects occur
Solution Approach 1:
The patent optimizes molecular parameters including substituent types, positions, and configurations to fine-tune receptor binding affinity ratios, achieving enhanced cognitive efficacy while minimizing side effect profiles through precise structural modification
Solution Approach 2:
The patent incorporates successful structural motifs from known antipsychotic compounds with favorable side effect profiles, copying beneficial structural features while avoiding problematic ones to create improved derivatives
4Reliability
If D3 receptor is blocked, then learning and memory improve, but D3 receptor mRNA is less distributed requiring 10 times stronger affinity than D2
Solution Approach 1:
The patent modifies molecular parameters to achieve differential binding affinity, creating compounds with selectively enhanced D3 affinity relative to D2 through specific structural features at key positions, thereby achieving cognitive effects at lower concentrations
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional groups that work synergistically to enhance D3 receptor selectivity and affinity, achieving the required 10-fold affinity difference through integrated structural design
5Object-affected harmful factors
If 5-HT2A receptor is antagonized, then negative symptoms improve and EPS side effects reduce, but overall therapeutic efficacy is limited without D3 selectivity
Solution Approach 1:
The patent merges 5-HT2A antagonism with selective D3 antagonism in a single compound, combining the benefits of reduced EPS from 5-HT2A blockade with cognitive improvement from selective D3 blockade, achieving enhanced overall efficacy
Data Source
AI summary
Disclosed in the present invention are a pyridinyl morpholine compound, a preparation method therefor, and an application thereof. The present invention provides a pyridinyl morpholine compound as represented by formula I, a pharmaceutically acceptable salt thereof or a hydrate of the pharmaceutically acceptable salt thereof. The compound can be used as an antagonist for one or more of D2, D3 or 5-HT2A, and is used for preparing a drug for treating schizophrenia.